efficacy endpoints

Related by string. efficacy endpoint * Efficacy . EFFICACY : primary efficacy endpoint . antimicrobial efficacy / Endpoints . EndPoint : Secondary endpoints include . video conferencing endpoints * secondary efficacy endpoints . primary efficacy endpoints . secondary efficacy endpoint . Secondary efficacy endpoints . Primary Efficacy Endpoint . Efficacy endpoints included *

Related by context. Frequent words. (Click for all words.) 75 secondary endpoints 71 primary endpoints 70 clinical endpoints 70 primary endpoint 70 primary efficacy endpoint 66 secondary endpoint 64 tolerability 64 pharmacodynamic 63 non inferiority 62 efficacy 60 dosing regimens 59 Phase Ib 59 clinically meaningful 59 Phase 2b study 59 dose limiting toxicities 58 pharmacokinetic 58 tolerability profile 58 ACTEMRA 58 AZD# 58 eculizumab 58 Zenvia 58 evaluable 58 statistical significance 58 telbivudine 57 picoplatin 57 DSMB 57 pharmacokinetic profile 57 commercialization milestones 57 Phase 2a clinical 56 Zerenex 56 Marqibo 56 randomized clinical trials 56 Phase IIa trial 56 Bronchitol 56 evaluable patients 56 Phase 2b clinical 56 ambrisentan 56 Phase IIa clinical 56 RCTs 56 Androxal 56 FTY# 55 endpoints 55 Phase 1b 55 LEVADEX 55 FOLOTYN 55 placebo controlled 55 unblinded 55 CYT# 55 mg dose 55 pralatrexate 55 demonstrated statistically significant 55 monotherapy 55 sunitinib 55 dose escalation 54 antitumor activity 54 pharmacokinetics 54 ticagrelor 54 statistically significant improvement 54 Phase III clinical 54 daclizumab 54 mg doses 54 ONGLYZA 54 Phase IIb clinical 54 Phase 2b trial 54 rivaroxaban 54 randomized controlled 54 immunogenicity 54 Phase IIb trial 54 HspE7 54 MGCD# [001] 54 MGCD# [002] 54 Entereg 54 clinical trial 54 pirfenidone 54 INCB# [002] 54 ASA# 54 LymphoStat B 54 randomized trials 53 randomized clinical 53 Phase III pivotal 53 Phase 2a 53 clinically relevant 53 Phase IIa 53 preclinical studies 53 lubiprostone 53 randomized placebo controlled 53 Phase III 53 randomized controlled trials 53 ADVEXIN 53 JANUVIA 53 meta analyzes 53 Phase 2b 53 mg BID 53 clinical trials 53 dose escalation study 53 CRx 53 panitumumab 53 pharmacodynamics 52 tiotropium 52 Phase III trials 52 Contrave

Back to home page